Stocks
Recursion Pharmaceuticals
AI-powered drug discovery platform.
Market data uses cached snapshots: prices refresh after 15 minutes, company details after 24 hours, and financials and corporate actions after 12 hours. Prices are completed-session closes, not live quotes.
Price snapshot retrieved . This is the retrieval time, not the trading-session time.
RXRX key data
About Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Recursion Pharmaceuticals websiteRXRX price chart
Daily open, high, low and close with volume.
Quotes are delayed at least 15 minutes.
RXRX technical indicators
Computed daily from RXRX's own price history — not third-party ratings. Technical analysis describes past price behaviour; it is information, not investment advice.
Fibonacci retracement
Based on RXRX's high/low over the same history as the chart above.
RXRX annual investment, R&D and cash flow
Quarterly highlights and original SEC reports
Verified annual USD facts from SEC filings. Collected .
| Annual period | Revenue | Cash capex | Productive asset purchases | Operating cash flow | Free cash flow | R&D | R&D / revenue |
|---|---|---|---|---|---|---|---|
| to | $74.68 million | $6.47 million | Not available | -$371.81 million | -$378.28 million | $475.27 million | 636.4% |
|
RevenueFromContractWithCustomerExcludingAssessedTax · 10-K filed · accession 0001601830-26-000039
NetCashProvidedByUsedInOperatingActivities · 10-K filed · accession 0001601830-26-000039
PaymentsToAcquirePropertyPlantAndEquipment · 10-K filed · accession 0001601830-26-000039
ResearchAndDevelopmentExpense · 10-K filed · accession 0001601830-26-000039
|
|||||||
| to | $58.84 million | $13.7 million | Not available | -$359.17 million | -$372.87 million | $314.42 million | 534.4% |
|
RevenueFromContractWithCustomerExcludingAssessedTax · 10-K filed · accession 0001601830-26-000039
NetCashProvidedByUsedInOperatingActivities · 10-K filed · accession 0001601830-26-000039
PaymentsToAcquirePropertyPlantAndEquipment · 10-K filed · accession 0001601830-26-000039
ResearchAndDevelopmentExpense · 10-K filed · accession 0001601830-26-000039
|
|||||||
| to | $44.58 million | $11.96 million | Not available | -$287.78 million | -$299.74 million | $241.23 million | 541.2% |
|
RevenueFromContractWithCustomerExcludingAssessedTax · 10-K filed · accession 0001601830-26-000039
NetCashProvidedByUsedInOperatingActivities · 10-K filed · accession 0001601830-26-000039
PaymentsToAcquirePropertyPlantAndEquipment · 10-K filed · accession 0001601830-26-000039
ResearchAndDevelopmentExpense · 10-K filed · accession 0001601830-26-000039
|
|||||||
| to | $39.84 million | $37.06 million | Not available | -$83.52 million | -$120.58 million | $155.7 million | 390.8% |
|
RevenueFromContractWithCustomerExcludingAssessedTax · 10-K filed · accession 0001601830-25-000035
NetCashProvidedByUsedInOperatingActivities · 10-K filed · accession 0001601830-25-000035
PaymentsToAcquirePropertyPlantAndEquipment · 10-K filed · accession 0001601830-25-000035
ResearchAndDevelopmentExpense · 10-K filed · accession 0001601830-25-000035
|
|||||||
SEC filing data: definitions, coverage and revisions
Source: the SEC Company Facts API, using standard US GAAP facts in USD from annual 10-K, 20-F or 40-F filings and amendments. Periods must span 300-400 days. Quarterly and year-to-date values are not presented as annual totals.
- Cash capex is cash payments to acquire property, plant and equipment. It excludes broader acquisition or intangible-asset tags and is not total AI spending or an estimate of finance-lease investment.
- Productive asset purchases are a separately reported, broader cash investment measure. They are shown in their own column and never substituted into PP&E capex, capital intensity or free cash flow. Do not rank mixed definitions as if they were identical.
- Free cash flow here is operating cash flow minus cash capex. It may differ from a company's adjusted free cash flow definition. If either input is missing, the result is omitted.
- R&D intensity is reported research and development expense divided by revenue from the same annual reporting period. Operating cash margin and capital intensity use the same-period revenue denominator.
- Figures are company-wide, not AI-specific or segment-level. Financial years differ, so compare the displayed start and end dates rather than assuming calendar-year alignment.
- The latest available filing for each supported fact is used, including restated comparative figures. Conflicting values from equally recent reports are omitted. Every figure retains its XBRL tag, accession and filing date.
Company-specific extension tags, IFRS-only data and unsupported definitions are not estimated. Missing standard facts are shown as unavailable, not zero. Data is refreshed in the background; the collection time is separate from the filing date.
RXRX frequently asked questions
What is the RXRX stock price today?
Recursion Pharmaceuticals (RXRX) last closed at $4.06 on October 27, 2026. Quotes are delayed at least 15 minutes.
What is the 52-week range for RXRX?
Over the past 52 weeks RXRX has traded between $2.77 and $6.50.
What is Recursion Pharmaceuticals's market cap?
Recursion Pharmaceuticals has a market capitalisation of about $1.98 billion.
Which exchange is RXRX listed on?
RXRX trades on NASDAQ, in the Biological Products, (No Diagnostic Substances) industry.
Is RXRX overbought or oversold?
RXRX's 14-day relative strength index (RSI) is 54.5, which is neutral on the standard 30/70 scale. RSI measures the speed of recent price moves, not a price target — this is not investment advice.
Is RXRX in an uptrend or downtrend?
RXRX's 50-day moving average is currently above its 200-day moving average — a Golden Cross (bullish long-term trend) in classic technical-analysis terms. Moving-average crossovers describe past price behaviour, not a forecast.